Nutrition and growth

Ramachandran, Prema

doi:10.4103/0971-5916.195066

Cited by 24 publications

(30 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Signs and symptoms include polydipsia (increase in thirst for water), polyuria (increase in the frequency of urination), polyphagia (increase in hunger or craving for food), unexpected weight loss, extreme fatigue or lack of energy, blurred vision, frequent or recurring infection or slow healing of cuts and bruises. Such symptoms can also be common in Type 1 Diabetes, an equal risk for T2D (Drivsholm, 2005; Ramachandran, 2014).…”

Section: Discussionmentioning

confidence: 99%

“…Such a situation arises due to a lack of cognition and awareness among the people. Similarly, Ramachandran (2014) also reported that the signs and symptoms of diabetes are disregarded by many because of the chronic progression of the disease. Therefore, it is important to initiate and impart the knowledge by giving more awareness to identify and diagnose different health complications, signs and symptoms.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Type 2 Diabetes and Its Signs and Symptoms Among the Meiteis of Manipur, India

Devi

Meitei

Singh

2022

Journal of the Anthropological Survey of India

View full text Add to dashboard Cite

The rate of prevalence of Type 2 Diabetes (T2D) increases globally and the greatest rise over the years is observed in India. T2D is the most frequent type of diabetes, increasing susceptibility to different diseases. The present study tries to find out the overall prevalence and identify the sign and symptoms of diabetes among the Meiteis of Manipur. Fasting blood glucose level was randomly collected from 1026 participants (men: 517 and women: 509) using a glucometer from five valley districts of Manipur. An interview schedule consisting of personal information and data on signs and symptoms of diabetes was collected from the participant with prior informed consent. The present study shows that 34.40% has impaired fasting glucose (IFG), and the overall prevalence of T2D is 12.96%, indicating that one out of every ten Meitei individuals is affected by the disease. The prevalence of T2D is higher with an increase in chronological age. The presence of signs and symptoms of T2D was significantly higher among the diabetic patients than the normal individuals. Owing to a lack of awareness and knowledge, the incidence of newly diagnosed diabetes is higher than self-reported. Therefore, as a preventive measure, there is an urgent need for timely intervention through awareness and imparting knowledge about diabetes education among the people.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Prevalence of Type 2 Diabetes and Its Signs and Symptoms Among the Meiteis of Manipur, India

Devi

Meitei

Singh

2022

Journal of the Anthropological Survey of India

View full text Add to dashboard Cite

show abstract

“…Given these hurdles, anti-VEGF therapy with bevacizumab may be chosen for the timely treatment of diabetic retinal complications. As visual disturbance is one of the first presentations of diabetes, and patients treated with bevacizumab often also receive a hypoglycemic agent with their diagnosis of diabetes [ 44 ]. Therefore, the HbA1c may be decreased after the bevacizumab treatment.…”

Section: Discussionmentioning

confidence: 99%

The Association of Intravitreal Injections of Different Anti-Vascular Endothelial Growth Factor with Systemic Outcomes in Diabetic Patients

Kang

Lin

Wang

et al. 2023

JPM

View full text Add to dashboard Cite

This retrospective cohort study aimed to assess the systemic effects of three commonly available anti-vascular endothelial growth factor intravitreal injections in patients with diabetes, using data taken from a multi-institutional database in Taiwan. Patient data were sourced from the multi-institutional Chang Gung Research Database. Participants were divided into groups based on treatment with bevacizumab, ranibizumab, or aflibercept. Baseline characteristics were matched among the groups by the inverse probability of treatment weighting. The incidence rate of outcome events was calculated as the number of events divided by 100 person-years of follow-up. The cumulative incidence function was used to estimate the incidence rate of the outcome events among groups. The incidence of ischemic stroke was higher in the ranibizumab group than the bevacizumab and aflibercept groups (1.65, 0.92, and 0.61 per 100 person-years, respectively). The incidence of major adverse lower-limb events was higher in the bevacizumab group (2.95), followed by ranibizumab (2.00) and aflibercept (0.74). Major bleeding was relatively higher in bevacizumab (12.1) compared to ranibizumab (4.3) and aflibercept (3.8). All-cause death was higher for both bevacizumab (3.26) and aflibercept (2.61) when compared to ranibizumab (0.55), and all-cause admission was found to be highest with bevacizumab (58.6), followed by aflibercept (30.2), and ranibizumab (27.6). The bevacizumab group demonstrated a greater decrease in glycated hemoglobin compared to the baseline level (−0.33%). However, a few differences in the clinical condition between the groups were still observed after matching. In conclusion, this study suggests that different anti-vascular endothelial growth factor agents may be associated with various and differing systemic adverse events. The differences might also be attributed to differences in patient characteristics and clinical status.

show abstract

“…Finally, we assessed these clinical and biochemical parameters for their association with type 2 diabetes-associated RAGE SNPs. Since diabetes and its complications remain asymptomatic until the appearance of the first symptoms or diagnosis, , it is crucial to detect them early to reverse, stop, or regress the progression of diabetes and its complications. Any association of SNPs with the risk of diabetes or diabetic nephropathy development can serve as a disease risk biomarker, enabling the screening of individuals vulnerable to disease development at a much earlier stage for early preventive measures.…”

Section: Introductionmentioning

confidence: 99%

Nanopore Sequencing of RAGE Gene Polymorphisms and Their Association with Type 2 Diabetes

et al. 2023

View full text Add to dashboard Cite

The receptor for advanced glycation end products (RAGE) is a transmembrane protein that interacts with its ligands, advanced glycation end products (AGEs). AGEs are elevated in diabetes and diabetic complications, leading to increased oxidative stress and activation of pro-inflammatory pathways facilitated by AGE−RAGE signaling. Polymorphisms in the RAGE gene can potentially affect AGE−RAGE interaction and its downstream signaling, which plays a crucial role in the progression of diabetes and its complications. In this study, we used nanopore sequencing for genotyping of RAGE polymorphism and identified a maximum number of 33 polymorphisms, including two previously unreported novel mutations in a cohort of healthy, type 2 diabetics without nephropathy and type 2 diabetics with nephropathy in order to identify associations. Two novel RAGE polymorphisms in the intron 8 and 3′UTR region at genomic locations 32181834 and 32181132, respectively, were detected with a low frequency. For four previously reported polymorphisms, cross-validation by PCR-RFLP showed 99.75% concordance with nanopore sequencing. Analysis of genotype distribution and allele frequencies revealed that five single nucleotide polymorphisms, i.e., rs1800625, rs3131300, rs3134940, rs2070600, and rs9391855, were associated with an increased risk for type 2 diabetes.

show abstract

Nutrition and growth

Cited by 24 publications

References 0 publications

Prevalence of Type 2 Diabetes and Its Signs and Symptoms Among the Meiteis of Manipur, India

Prevalence of Type 2 Diabetes and Its Signs and Symptoms Among the Meiteis of Manipur, India

The Association of Intravitreal Injections of Different Anti-Vascular Endothelial Growth Factor with Systemic Outcomes in Diabetic Patients

Nanopore Sequencing of RAGE Gene Polymorphisms and Their Association with Type 2 Diabetes

Contact Info

Product

Resources

About